A revolutionary nano-particle delivery system for cannabis provides a Star Trek moment
NanoSphere Health Sciences Inc. (CSE: NSHS) (“NanoSphere”) is a nano-biotechnology company based in Greenwood Village, Colorado, USA. NanoSphere is a company paving the way in the development of innovative delivery systems for cannabinoids, medications, nutrients, and animal health. The Company provides the only patented nano-particle delivery system to transport the highest level of therapeutic agents directly to the bloodstream for maximum absorbency.
Evolve Formulas – Transdermal NanoSerum
NanoSphere’s Evolve Formulas is the provider of the world’s first and only scientifically proven nano-particle delivery system for cannabis. Evolve’s pioneering product, Transdermal NanoSerum™, is a fast-acting, ultra-strength transdermal formula infused with nano-encapsulated cannabis and cannabis extracts. NanoSphere’s delivery system makes particles easy to absorb and completely bypasses the gastrointestinal tract and respiratory system. Only 6% of edible cannabis and 20% smoking cannabis enters the body.
NanoSerum™ immediately penetrates the skin to deliver direct-focused results and intelligently carries a full spectrum of cannabinoids and phytochemicals to receptors throughout the body for systemic healing.
Now I am thinking, I have seen this on an episode of Star Trek. In the world of Star Trek, there’s no need for needles as the Doctor administers medicine through the skin using a painless jet-injected hypo-spray. Considering this is a TV series from the 1960s, several futuristic ideas are already commercially viable on today’s market – The cell phone (Flip Phone), laptops and tablet computers, 3D printers (replicators, still waiting for the food version though), large screen TVs and much more.
NanoSpehere is winning technology innovation awards
In recognition of the innovative and disruptive work the company is doing, NanoSphere has been recognized with a nomination from the National Cannabis Industry Association (NCIA) for the Excellence in Technology award in infused products and extraction. The award is granted to a company that has developed a new technology that will have a lasting effect on the industry. NanoSphere Chief Science Officer Dr. Richard Kaufman said: “It comes as no surprise to us that our technology is being recognized for its market disruption. We are proud of our achievements so far in the nano-particle delivery space and look forward to advancing our technology with new applications and new markets.” This delivery platform, was also recently awarded the Frost and Sullivan 2018 Best Practices Award for Technological Innovation.
In recent news (July 31, 2018), NanoSphere announced they had entered into a partnership with Delta 9 Cannabis INC to bring products from its cannabis brand, Evolve Formulas, into the Canadian market. Delta 9 shares NanoSphere’s vision for bringing innovative and reliable products to market for recreational and medical consumers alike in the only G7 nation that has legalized cannabis for both purposes. Under the agreement, Delta 9 and NanoSphere will each receive 50 percent of the net revenue from sale of Evolve Formulas products. The initial term of the agreement is 36 months following the date of the first commercial sale of licensed products. Delta 9 is a licensed producer of marijuana and operates an 80,000 square foot production facility in Winnipeg, Canada.
NanoSphere Health Sciences Inc. has a market cap of C$ 42 m. The Company is only just now starting commercial sales of their products, so revenue figures will start to follow soon.
How many of today’s innovators have been inspired by the Star Trek TV show. This technology has the potential to change the way medicine is delivered efficiently to the body. It will have needle phobia people and parents dancing in the street. The potential for the Company to expand into new markets is enormous. So for now investors can look to buy some shares in NanoSphere, watch some more Star Trek shows, and keep a close eye on the progress of NanoSphere.
Matthew Bohlsen is a Senior Editor for InvestorIntel.com. With a Graduate Diploma in Applied Finance and Investment, and a Graduate Diploma in Financial Planning. He ... <Read more about Matthew Bohlsen>